Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFORT study of FOLFIRI plus aflibercept after progression on FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
jRCTs071190003Completed
- Sponsor
- Sanofi
- Start
- Jun 2019
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Sanofi. Primary endpoint: Progression-free survival. Started Jun 2019; status: completed.
02
Drugs
afliberceptirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs071190003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190003.